Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

Not Applicable

Withdrawn

• Conditions: Primary and Secondary Pulmonary Hypertension

• Registration Number: NCT00155714
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension

Detailed Description

Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil. Efficacy of inhaled NO and Iloprost will also be compared.

Study Timeline

• Study Start: 2002-11
• Study Completion: 2005-05
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-12
• Status Verified: 2010-01
• Last Update Submitted: 2010-03-15
• Last Update Posted: 2010-03-16

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients with primary and secondary pulmonary arterial hypertension

Exclusion Criteria

Unstable patients or patients with allergy to sildenafil

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
6 min walking distance
WHO functional status
PaO2
mean pulmonary artery pressure

Secondary Outcome Measures

Name	Time	Method
cardiac output
VO2max

Trial Locations

Locations (1)

Ping-Hung Kuo; 🇨🇳 Taipei, Taiwan